{
    "clinical_study": {
        "@rank": "14886", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)"
            }, 
            {
                "arm_group_label": "G-CSF", 
                "arm_group_type": "Experimental", 
                "description": "G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "After successful screening, first the investigators first treat patients of severe alcoholic\n      hepatitis with steroids for 7 days. Patients who are found to be unresponsive as per Lille's\n      score [>0.45] would be randomized into either placebo group or G-CSF group.  Responders to\n      steroids will continue on steroids for 28 days followed by 2 weeks of tapering. Non\n      responders will be randomized to receive G-CSF for 28days."
        }, 
        "brief_title": "Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Alcoholic Hepatitis", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Severe alcoholic hepatitis patients [Maddrey's score > 32] aged between 18 to 65 years.\n\n        Exclusion Criteria:\n\n          -  Presence of active infections\n\n          -  Acute GI bleed\n\n          -  Hepatorenal syndrome\n\n          -  Patient unwilling\n\n          -  DF>120\n\n          -  Autoimmune hepatitis\n\n          -  Hepatitis B, Hepatitis C, HIV cases\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820208", 
            "org_study_id": "ILBS- AH-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.", 
                "intervention_name": "G-CSF", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "G-CSF", 
                "description": "Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "shasthry@gmail.com", 
                "last_name": "Dr Shasthry SM, MD", 
                "phone": "+91-11-01146300000"
            }, 
            "contact_backup": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "+91-11-01146300000"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of liver and Biliary Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial.", 
        "overall_contact": {
            "email": "shasthry@gmail.com", 
            "last_name": "Dr Shasthry SM, MD", 
            "phone": "+91-11-01146300000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Survival of subjects in both group", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in child score at 4 week and 12 weeks compared to baseline in both groups.", 
                "measure": "Improvement in Child's score in steroid unresponsive patients with severe alcoholic hepatitis patients", 
                "safety_issue": "No", 
                "time_frame": "4 weeks and 12 weeks"
            }, 
            {
                "description": "Change in MELD score at 4 week and 12 weeks compared to baseline in both groups", 
                "measure": "Improvement in MELD score in steroid unresponsive patients with severe alcoholic hepatitis patients", 
                "safety_issue": "No", 
                "time_frame": "4 weeks and 12 weeks"
            }
        ], 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2015", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}